» Articles » PMID: 21161463

Randomized Transcoronary Delivery of CD34(+) Cells with Perfusion Versus Stop-flow Method in Patients with Recent Myocardial Infarction: Early Cardiac Retention of ⁹⁹(m)Tc-labeled Cells Activity

Abstract

Background: For transcoronary progenitor cells' administration, injections under flow arrest (over-the-wire balloon technique, OTW) are used universally despite lack of evidence for being required for cell delivery or being effective in stimulating myocardial engraftment. Flow-mediated endothelial rolling is mandatory for subsequent cell adhesion and extravasation.

Methods: To optimize cell directing toward the coronary endothelium under maintained flow, the authors developed a cell-delivery side-holed perfusion catheter (PC). Thirty-four patients (36-69 years, 30 men) with primary stent-assisted angioplasty-treated anterior MI (peak TnI 151 [53-356]ng/dL, mean[range]) were randomly assigned to OTW or PC autologous ⁹⁹Tc-extametazime-labeled bone marrow CD34(+) cells (4.34 [0.92-7.54] × 10⁶) administration at 6-14 days after pPCI (LVEF 37.1 [24-44]%). Myocardial perfusion (⁹⁹(m)Tc-MIBI) and labeled cells' activity were evaluated (SPECT) at, respectively, 36-48 h prior to and 60 min after delivery.

Results: In contrast to OTW coronary occlusions, no intolerance or ventricular arrhythmia occurred with PC cells' administration (P < .001). One hour after delivery, 4.86 [1.7-7.6]% and 5.05 [2.2-9.9]% activity was detected in the myocardium (OTW and PC, respectively, P = .84). Labeled cell activity was clearly limited to the (viable) peri-infarct zone in 88% patients, indicating that the infarct core zone may be largely inaccessible to transcoronary-administered cells.

Conclusions: Irrespective of the transcoronary delivery method, only ≈ 5% of native (i.e., non-engineered) CD34(+) cells spontaneously home to the injured myocardium, and cell retention occurs preferentially in the viable peri-infarct zone. Although the efficacy of cell delivery is not increased with the perfusion method, by avoiding provoking ischemic episodes PC offers a rational alternative to the OTW delivery.

Citing Articles

Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.

Gold D, Sandesara P, Kindya B, Gold M, Jain V, Vatsa N Int J Cardiol. 2024; 407:132104.

PMID: 38677332 PMC: 11559591. DOI: 10.1016/j.ijcard.2024.132104.


Infarct size and long-term left ventricular remodelling in acute myocardial infarction patients subjected to transcoronary delivery of progenitor cells.

Czyz L, Tekieli L, Miszalski-Jamka T, Banys R, Szot W, Mazur W Postepy Kardiol Interwencyjnej. 2023; 18(4):465-471.

PMID: 36967855 PMC: 10031670. DOI: 10.5114/aic.2023.125079.


Safety and efficacy of transcoronary transfer of human neonatal stem cells to ischemic myocardium using a novel cell-delivery system (CIRCULATE catheter) in swine model of acute myocardial infarction.

Bilewska A, Abdullah M, Mishra R, Musialek P, Gunasekaran M, Saha P Postepy Kardiol Interwencyjnej. 2023; 18(4):431-438.

PMID: 36967844 PMC: 10031680. DOI: 10.5114/aic.2022.121697.


Acute myocardial infarction reparation/regeneration strategy using Wharton's jelly multipotent stem cells as an 'unlimited' therapeutic agent: 3-year outcomes in a pilot cohort of the CIRCULATE-AMI trial.

Kwiecien E, Drabik L, Mazurek A, Jarocha D, Urbanczyk M, Szot W Postepy Kardiol Interwencyjnej. 2023; 18(4):476-482.

PMID: 36967843 PMC: 10031665. DOI: 10.5114/aic.2022.121125.


Transcoronary stem cell transfer and evolution of infarct-related artery atherosclerosis: evaluation with conventional and novel imaging techniques including Quantitative Virtual Histology (qVH).

Dabrowski W, Tekieli L, Mazurek A, Lanocha M, Banys R, Zmudka K Postepy Kardiol Interwencyjnej. 2023; 18(4):483-495.

PMID: 36967840 PMC: 10031661. DOI: 10.5114/aic.2023.125609.


References
1.
Donahue J, Heldman A, Fraser H, McDonald A, Miller J, Rade J . Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000; 6(12):1395-8. DOI: 10.1038/82214. View

2.
Schachinger V, Aicher A, Dobert N, Rover R, Diener J, Fichtlscherer S . Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation. 2008; 118(14):1425-32. DOI: 10.1161/CIRCULATIONAHA.108.777102. View

3.
Salmi M, Jalkanen S . Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol. 2005; 5(10):760-71. DOI: 10.1038/nri1705. View

4.
Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N . Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106(24):3009-17. DOI: 10.1161/01.cir.0000043246.74879.cd. View

5.
Penicka M, Lang O, Widimsky P, Kobylka P, Kozak T, Vanek T . One-day kinetics of myocardial engraftment after intracoronary injection of bone marrow mononuclear cells in patients with acute and chronic myocardial infarction. Heart. 2007; 93(7):837-41. PMC: 1994434. DOI: 10.1136/hrt.2006.091934. View